Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF

IPF Clinical Trial

Official title:

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of Inhaled AGMB-447 in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06181370
• Other study ID #: AGMB-447-C101
• Status: Recruiting
• Phase: Phase 1
• Start date: December 1, 2023
• Est. completion date: March 2025

Study information

• Verified date: March 2024
• Source: Agomab Therapeutics NV
• Contact: Tim Van Kaem
• Phone: +3233023530
• Email: clinicalstudies[@]agomab.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to measure the safety, tolerability PK and PD of inhaled AGMB-477 compared with placebo in healthy participants and participants with IPF. This is an integrated phase 1, single center, 3-part, double-blind, randomized, placebo-controlled SAD (Part A) and MAD (Part B) study in healthy participants and multiple dose study in IPF participants (Part C). Safety, tolerability PK and PD will be assessed following single ascending, multiple ascending and multiple dosing of AGMB-447 administered via nebulizer in Part A, B and C, respectively.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 76
• Est. completion date: March 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion criteria for Healthy Participants (Parts A and B):

• Male and female participants aged between 18-55 years inclusive, at the time of informed consent.

• Participants must have FEV1 =80% predicted at screening and prior to randomization on Day -1 or Day 1 of treatment period 1 (using Global Lung Index, GLI 2012, predicted values).

• Participant must have a body weight of at least 50.0 kg and BMI = 18 and = 32 kg/m2 at screening.

• Participants must be in good health as determined by medical history, physical examination, vital signs, 12-lead ECG, spirometry and clinical laboratory assessments at the time of screening, as judged by the Investigator.

Inclusion Criteria for IPF Participants (Part C)

• Male and female participants aged >40 years inclusive, at the time of informed consent.

• Participants must have a confirmed diagnosis of IPF (IPF based on 2022 ATS/ERS/JRS/ALAT Guidelines) as confirmed by the Investigator based on chest High Resolution Computed Tomography Scan taken within 5 years of screening and, only if available, surgical lung biopsy)

• Participants must be either:

• Receiving a stable, well tolerated dose of Nintedanib for 3 months prior to screening for the treatment of IPF

• OR

• Receiving no current antifibrotic medication for the treatment of IPF. This includes those who have never received treatment and those who have stopped medication due to intolerance for any reason, except non-responsiveness, for at least 6 weeks prior to screening.

• Participants must have FVC =50% of predicted (using Global Lung Index, GLI 2012, predicted values) at screening.

• Participants must have DLCO (corrected for hemoglobin ) = 35% of predicted (using Global Lung Index, GLI 2017, predicted values) at screening.

• Participants must have FEV1 =40% predicted at screening and prior to randomization on Day -1 or Day 1 (using Global Lung Index, GLI 2012, predicted values).

Exclusion criteria for Healthy Participants (Parts A and B)

• History or presence of any clinically relevant acute or chronic medical or psychiatric condition that could interfere with the participant's safety during the clinical study or expose the participant to undue risk as judged by the Investigator.

• After a minimum of 10 minutes supine rest at the time of screening or prior to randomization on Day -1 or Day 1 of treatment period 1:

• Systolic blood pressure <90 or >150 mmHg, or

• Diastolic blood pressure <50 or >95 mmHg, or

• Pulse <40 or >90 bpm

• Any clinically significant abnormalities in resting ECG at the time of screening or prior to randomization on Day -1 or Day 1 of treatment period 1 including prolonged QTcF (>450 ms for males; >470 ms for females using the mean of triplicate ECG's) and cardiac arrhythmias, as judged by the Investigator.

• Clinically significant abnormalities in renal function at screening including any of the following:

• Serum creatinine >2 x ULN

• eGFR <80 mL/min

• Clinically significant abnormalities in liver function at screening including any of the following:

• Bilirubin >1.5 x ULN

• Aminotransferases >2 x ULN

• ALP >1.5 x ULN

Exclusion Criteria for IPF Participants (Part C)

• History or presence of any clinically relevant acute or chronic medical or psychiatric condition that could interfere with the participant's safety during the clinical study or expose the participant to undue risk as judged by the Investigator.

• History or presence of any clinically significant pulmonary abnormalities, with the exception of IPF, in the opinion of the Investigator.

• Relevant airways obstruction (pre-bronchodilator FEV1/ FVC < 0.7) at screening.

• Any clinically significant abnormalities in resting ECG at the time of screening or prior to randomization on Day -1 or Day 1 including prolonged QTcF (>450 ms for males; >470 ms for females using the mean of triplicate ECG's) and cardiac arrhythmias, as judged by the Investigator.

• Clinically significant abnormalities in liver function at screening including any of the following:

• Bilirubin >1.5 x ULN

• Aminotransferases >2 x ULN

• ALP >1.5 x ULN

• Acute IPF exacerbation within 3 months prior to screening and/or during the screening period prior to dose on Day 1 as determined by the Investigator.

• Any signs of respiratory tract infection within 4 weeks of screening or prior to dosing on Day 1 that is deemed clinically significant in the opinion of the Investigator.

• Malignancy within the past 5 years of screening with the exception of in situ removal of basal cell carcinoma or resected benign colonic polyps.

Related Conditions & MeSH terms

• IPF

Intervention

Drug:
• AGMB-447
AGMB-447 inhaled drug

Other:
• placebo
placebo inhaled drug

Locations

Country	Name	City	State
United Kingdom	Medicines Evaluation Unit	Manchester

Sponsors (1)

Lead Sponsor	Collaborator
Agomab Spain S.L.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events	To evaluate the safety and tolerability of AGMB-447 in terms of AE at every visit	From Screening Through Study Completion, up to 8 Weeks
Primary	Number of participants with abnormal clinical laboratory values	To evaluate the safety and tolerability of AGMB-129 in terms of abnormal laboratory parameters at every visit	From Screening Through Study Completion, up to 8 Weeks
Primary	Number of participants with abnormal ECG parameters	To evaluate the safety and tolerability of AGMB-447 in terms of abnormal ECGs at every visit	From Screening Through Study Completion, up to 8 Weeks
Primary	Number of participants with abnormal vital signs	To evaluate the safety and tolerability of AGMB-447 in terms of vital signs at every visit	From Screening Through Study Completion, up to 8 Weeks
Primary	Number of participants with abnormal physical exams	To evaluate the safety and tolerability of AGMB-447 in terms of physical exams at every visit	From Screening Through Study Completion, up to 8 Weeks
Primary	Number of participants with abnormal spirometry parameters	To evaluate the safety and tolerability of AGMB-447 in terms of spirometry at every visit	From Screening Through Study Completion, up to 8 Weeks
Secondary	Plasma levels of AGMB-447	To characterize the pharmacokinetics (PK) of AGMB-447 by measuring the amount in plasma	From Screening Through Study Completion, up to 8 Weeks
Secondary	Plasma levels of the major metabolite	To characterize the pharmacokinetics (PK) of the major metabolite by measuring the amount in plasma	From Screening Through Study Completion, up to 8 Weeks